Madrigal (MDGL) came out with a quarterly loss of $7.10 per share versus the Zacks Consensus Estimate of a loss of $7.55. This compares to loss of $4.69 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.96%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $6.06 per share when it actually produced a loss of $7.38, delivering a surprise of -21.78%. Over the last four quarters, the company ...

Second-quarter 2024 net sales of $14.6 million Rezdiffra™ (resmetirom) coverage in place for more than 50 percent of commercial lives; less than 5 percent of Rezdiffra-covered lives require biopsy Expert guidelines recommend Rezdiffra as first-line therapy for patients with F2/F3 NASH/MASH Plans to directly commercialize resmetirom in Europe following EMA decision expected mid-year 2025 Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion at June 30, 2024 Company to host ...

CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Shannon is an outstanding leader who brings a wealth of expertise to her new role as General Counsel. She joined the Madrigal team in 2024 as Chief ...

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com. The webcast will be available approximately two hours after the live webcast. Following the announcement, Madrigal's ma ...

With such a favorable setup, could it be the case that an investment in it made today would lead to building wealth on the scale of $1 million? It's not as unlikely as it sounds, so let's look at the details. First, the value of the stock would need to go up by a vast amount over the next decade or two, likely on the order of 10 to 20 times. Second, the investor would need to have committed sufficient capital for that multiplicative growth to yield at least $1 million. In the case of the stock rising by 10X ...

Madrigal Pharmaceuticals (MDGL 0.21%) is in a position that most other biotechs envy. Its first medicine just hit the market, sales are due to start rolling in, and there aren't any other companies that can slow it down -- for now, that is. It'll be growing, and likely quickly While Rezdiffra is only indicated to treat patients with moderate-to-severe fibrosis (scarring) of the liver, the company plans to continue with its research and development (R&D) activities to test its helpfulness in the context of m ...

Now, the picture is shifting, and the odds are good that one of these players will pull ahead of the other, thereby becoming the better biotech-stock investment. The only questions are, which will it be, and for how long will it last? Let's dive in. In the future, the company hopes to pick up an indication for more severe forms of fibrosis as well as cirrhosis, and it's currently pursuing clinical trials on that front. Being able to treat cirrhosis would expand its addressable market significantly, but inve ...

"The qFibrosis data provide support for Rezdiffra's potential in benefiting patients with NASH with moderate to advanced liver fibrosis by reversing fibrosis and preventing progression to more advanced liver disease," said Jörn M. Schattenberg, M.D., Professor of Medicine and Director of the Department of Medicine at the University Medical Center Homburg and University of the Saarland in Germany. "These results, coupled with earlier analyses of the SteatoSITE database which found that reduced THR-β activity ...

It's not the most prominent biotech, but it has an important claim to fame. Madrigal Pharmaceuticals' (MDGL -0.79%) shares are down by 27% over the past year, while the S&P 500 is up by 26%. However, this poor performance hardly reflects the progress the biotech has made. Madrigal recently earned regulatory approval for Rezdiffra, a therapy for non-alcoholic steatohepatitis (NASH). Not only was Rezdiffra Madrigal's first product on the market, but it is also the first and only approved by the U.S. Food and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Table of Contents OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33277 _________________________ MADRIGAL PHARMACEUTICALS, INC. (Exact name of regis ...